Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

714 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
NOD2/CARD15 does not influence response to infliximab in Crohn's disease.
Vermeire S, Louis E, Rutgeerts P, De Vos M, Van Gossum A, Belaiche J, Pescatore P, Fiasse R, Pelckmans P, Vlietinck R, Merlin F, Zouali H, Thomas G, Colombel JF, Hugot JP; Belgian Group of Infliximab Expanded Access Program and Fondation Jean Dausset CEPH, Paris, France. Vermeire S, et al. Gastroenterology. 2002 Jul;123(1):106-11. doi: 10.1053/gast.2002.34172. Gastroenterology. 2002. PMID: 12105838
Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease.
Vermeire S, Louis E, Carbonez A, Van Assche G, Noman M, Belaiche J, De Vos M, Van Gossum A, Pescatore P, Fiasse R, Pelckmans P, Reynaert H, D'Haens G, Rutgeerts P; Belgian Group of Infliximab Expanded Access Program in Crohn's Disease. Vermeire S, et al. Am J Gastroenterol. 2002 Sep;97(9):2357-63. doi: 10.1111/j.1572-0241.2002.05991.x. Am J Gastroenterol. 2002. PMID: 12358256
NOD2/CARD15: relevance in clinical practice.
Vermeire S. Vermeire S. Best Pract Res Clin Gastroenterol. 2004 Jun;18(3):569-75. doi: 10.1016/j.bpg.2003.12.008. Best Pract Res Clin Gastroenterol. 2004. PMID: 15157828 Review.
Optimizing anti-TNF treatment in inflammatory bowel disease.
Rutgeerts P, Van Assche G, Vermeire S. Rutgeerts P, et al. Among authors: vermeire s. Gastroenterology. 2004 May;126(6):1593-610. doi: 10.1053/j.gastro.2004.02.070. Gastroenterology. 2004. PMID: 15168370 Review.
714 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page